Larger Testicular Volume Is Independently Associated with Favorable Indices of Lung Function

Tae Beom Kim, M.D.¹ and I-Nae Park, M.D.²
¹Department of Urology, Gachon University Gil Medical Center, Incheon, ²Department of Pulmonology, Inje University Seoul Paik Hospital, Seoul, Korea

Background: Men with chronic obstructive pulmonary disease, have reduced endogenous testosterone levels, but the relationship between pulmonary function and endogenous testosterone levels, is inconsistent. Testicular volume is a known indicator of endogenous testosterone levels, male fertility, and male potency. In the present study, the authors investigated the relationship, between testicular volume and lung function.

Methods: One hundred and eighty-one South Korean men age 40–70, hospitalized for urological surgery, were retrospectively enrolled, irrespective of the presence of respiratory disease. Study subjects underwent pulmonary function testing, prior to procedures, and testicular volumes were measured by orchidometry. Testosterone levels of patients in blood samples collected between 7 AM and 11 AM, were measured by a direct chemiluminescent immunoassay.

Results: The 181 study subjects were divided into two groups, by testicular volume (≥35 mL vs. <35 mL), the larger testes group, had better lung functions (forced vital capacity [FVC]: 3.87±0.65 L vs. 3.66±0.65 L, p=0.037; forced expiratory volume in 1 second [FEV₁]: 2.92±0.57 L vs. 2.65±0.61 L, p=0.002; FVC % predicted: 98.2±15.2% vs. 93.8±13.1%, p=0.040; FEV₁ % predicted: 105.4±19.5% vs. 95.9±21.2%, p=0.002). In addition, the proportion of patients with a FEV₁/FVC of <70%, was lower in the larger testes group. Univariate analysis conducted using linear regression models, revealed that testicular volume was correlated with FVC (r=0.162, p=0.029), FEV₁ (r=0.218, p=0.003), FEV₁/FVC (r=0.149, p=0.046), and FEV₁ % predicted (r=0.178, p=0.017), and multivariate analysis using linear regression models, revealed that testicular volume was a significant predictive factor for FEV₁ % predicted (β =0.159, p=0.041).

Conclusion: Larger testicular volume was independently associated, with favorable indices of lung function. These results suggest that androgens, may contribute to better lung function.

Keywords: Respiratory Physiological Phenomena; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Testis; Testosterone
able testosterone may decline more rapidly than total testosterone.5

Several studies have shown that middle aged and elderly COPD patients may develop hypogonadism, and the prevalence of hypogonadism in men with COPD can range from 22% to 69%. In addition, hypogonadism has been associated with several other systemic manifestations including osteoporosis, depression, and muscle weakness.2,6,8 However, information regarding the relationship between pulmonary function and endogenous testosterone levels in general populations is inconsistent.5–7. Discrepancies can be mainly attributed to small sample sizes, different patient selection criteria, and circadian variations in testosterone levels. Early morning testosterone levels in young males are, on average, 50% higher than afternoon levels, and reference ranges have usually been derived using morning specimens. Furthermore, testosterone levels can fluctuate substantially on a day-to-day basis. It has been recommended that androgen status should be assessed using more than one measurement.10

Testicular volume has been shown to well represent endogenous testosterone levels, and thus, is considered as an indicator of endogenous testosterone level, fertility, and potency. Furthermore, unlike testosterone levels, testicular volumes do not fluctuate markedly, and in fact, are relatively stable. Testicular volumes have been found to vary widely between individuals in large-scale studies.11–16 Furthermore, like lung function,18 testicular volume decreases with aging.19,20 Therefore, in the present study, we have investigated the relationship between testicular volume and pulmonary function.

Materials and Methods

1. Study subject selection

One hundred and eighty-one South Korean male patients (aged 40–70 years) hospitalized for urological surgery between April 2014 and March 2016 at a single tertiary academic center were retrospectively reviewed irrespective of the presence of respiratory disease. Testosterone levels of all the patients in blood samples collected between 7 AM and 11 AM were measured by a direct chemiluminescent immunoassay (Bayer ADVIA Centaur; assay range, 10–1,500 ng/dL). Regarding smoking histories, “never-smokers” were defined as those who had smoked on average <1 cigarette/day for <6 months or had never smoked. For ever-smokers, pack-years were calculated to quantify tobacco use; 1-pack-year was equivalent to smoking an average of 20 cigarettes per day for 1 year.

2. Pulmonary function tests

All study subjects underwent spirometry according to American Thoracic Society guidelines,21,22 before procedures. Spirometry indices included the forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC ratio. Post-bronchodilator responses were not measured.

3. Testicular volume

Patients with conditions known to strongly influence testicular volume were excluded from the study. Testicular volumes were measured by an experienced urologist using an orchidometer.

4. Statistics

Relationships between the variables were analyzed using Pearson's linear correlation. Univariate and multivariate analyses were performed using linear regression modelling to identify independent predictors of lung factor. The Student's t test and the chi-square test were used to compare the variables of the two study groups divided by testicular volume (≥35 mL vs. <35 mL).

The analysis was performed using SPSS version 12.0 (SPSS Inc., Chicago, IL, USA), and p-values of <0.05 were considered statistically significant.

5. Ethics statement

The study was approved by the Institutional Review Board of Gachon University Gil Hospital (GBIRB2016-175) and conducted in accordance with the Declaration of Helsinki. The informed consent requirement was waived due to the retrospective study design.

Results

1. Correlation study

The characteristics of the 181 study subjects are summarized in Table 1.

Univariate analysis using linear regression models showed that testicular volume was correlated with FVC (r=0.162, p=0.029), FEV1 (r=0.218, p=0.003), FEV1/FVC (r=0.149, p=0.046), and FEV1 % predicted (r=0.178, p=0.017) (Table 2). Multivariate analysis using linear regression models showed that testicular volume significantly predicted FEV1 % predicted (β=0.159, p=0.041) (Table 3).

2. Comparison study between the two study groups (testicular volume ≥35 mL vs. testicular volume <35 mL)

The larger testes group (n=88) had better lung functions than the smaller testes group (n=93) (FVC: 3.87±0.65 L vs.
3.66±0.65 L, p=0.037; FEV₁: 2.92±0.57 L vs. 2.65±0.61 L, p=0.002; FEV₁/FVC: 75.5±7.8% vs. 71.9±10.5%, p=0.009; FVC % predicted: 98.2±15.2% vs. 93.8±13.1%, p=0.040; FEV₁ % predicted: 105.4±19.5% vs. 95.9±21.2%, p=0.002) (Table 4). Furthermore, the percentage of patients with a FEV₁/FVC of <70% was lower in the larger testes group (15.9% [14/88] vs. 29.0% [27/93], p=0.034) (Table 4).

3. Smoking

Out of the 181 study subjects, 80 (44.2%) were ever-smokers, and the mean smoking exposure of smokers was 30.2±20.5 pack-years (Table 1). Univariate analysis using linear regression models showed that testicular volume was not correlated with smoking (r=–0.094, p=0.216) (Table 2). When patients were divided into two groups according to testicular volume (testicular volume, ≥35 mL vs. <35 mL), proportions of ever-smokers and mean smoking exposure of ever-smokers were not different between the two groups (Table 4).

4. Odds ratio analysis

The odds ratio of ever-smokers in the larger versus the smaller testes group was 1.104, which was not statistically significant (95% confidence interval [CI], 0.614–1.986). However, the odds ratio of having a FEV₁/FVC ≥70% in the larger testes group versus the smaller testes group was 2.162, which was

| Characteristic | Mean±SD | Median (min–max) |
|---------------|---------|------------------|
| Age, yr       | 64.4±4.6 | 65.0 (44.0–70.0) |
| Height, cm    | 167.7±5.8 | 168.0 (154.0–182.0) |
| Weight, kg    | 67.6±9.5 | 67.0 (49.0–97.0) |
| BMI, kg/m²    | 24.0±2.8 | 23.9 (17.0–32.3) |
| Testosterone, ng/dL | 379.8±148.3 | 377.0 (109.6–771.0) |
| Free testosterone, pg/mL | 7.94±2.98 | 7.81 (1.28–17.87) |
| Testicular volume, mL | 34.7±9.2 | 34.0 (15.0–54.0) |
| FVC, L | 3.76±0.65 | 3.81 (1.75–5.63) |
| FEV₁, L | 2.78±0.61 | 2.80 (0.82–4.36) |
| FEV₁/FVC, % | 73.6±9.4 | 76.0 (26.0–87.0) |
| PredFVC, % | 95.9±14.3 | 97.0 (45.0–128.0) |
| PredFEV₁, % | 100.5±20.9 | 101.0 (33.0–182.0) |
| Smoker, n (%) | 80/181 (44.2) |
| Smoking, pack-years | 30.2±20.5 | 25.0 (2.0–100.0) |
| FEV₁/FVC<70%, n (%) | 41/181 (22.7) |

BMI: body mass index; FVC: forced vital capacity; FEV₁: forced expiratory volume in 1 second; PredFVC: FVC % predicted; PredFEV₁: FEV₁ % predicted.

| Characteristic | r-value | p-value |
|---------------|---------|---------|
| Age           | -0.405  | 0.000   |
| Height        | 0.478   | 0.000   |
| Weight        | 0.286   | 0.000   |
| BMI           | 0.070   | 0.000   |
| TV            | 0.019   | 0.004   |
| fT            | 0.094   | 0.212   |
| TV            | 0.162   | 0.029   |
| Smoking       | -0.108  | 0.153   |

PFT: pulmonary function test; FVC: forced vital capacity; FEV₁: forced expiratory volume in 1 second; PredFVC: FVC % predicted; PredFEV₁: FEV₁ % predicted; TV: testicular volume; T: testosterone; r-value: Pearson correlation coefficient; BMI: body mass index; fT: free testosterone.
Discussion

This is the first study undertaken to investigate whether a relation exists between testicular volume and pulmonary function. It shows testicular volume is positively and independently associated with better lung functions. Furthermore, the proportion of patients with a FEV1/FVC <70% was lower in the larger testes group, and multivariate analysis using linear regression models showed that testicular volume was a significant predictive factor for FEV1 % predicted independently of smoking.

Table 3. Multivariate analysis using linear regression models (n=181)

|                     | FVC       | FEV1      | FEV1/FVC  | PredFVC   | PredFEV1   |
|---------------------|-----------|-----------|-----------|-----------|------------|
| Age β               | -0.289    | -0.294    | -0.083    | -0.123    | -0.050     |
| p-value             | 0.000     | 0.000     | 0.285     | 0.121     | 0.523      |
| Height β            | 0.419     | 0.251     | -0.123    | 0.005     | -0.064     |
| p-value             | 0.000     | 0.002     | 0.185     | 0.961     | 0.491      |
| Weight β            | -0.026    | 0.011     | 0.069     | -0.099    | -0.024     |
| p-value             | 0.744     | 0.894     | 0.456     | 0.292     | 0.794      |
| Testosterone β      | 0.046     | 0.032     | 0.009     | 0.085     | 0.070      |
| p-value             | 0.470     | 0.622     | 0.904     | 0.260     | 0.344      |
| Testicular volume β | 0.036     | 0.109     | 0.127     | 0.110     | 0.159      |
| p-value             | 0.585     | 0.112     | 0.102     | 0.162     | 0.041      |
| Smoking β           | -0.075    | -0.174    | -0.189    | -0.085    | -0.187     |
| p-value             | 0.242     | 0.010     | 0.013     | 0.265     | 0.014      |

FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; PredFVC: FVC % predicted; PredFEV1: FEV1 % predicted.

Table 4. Characteristics of patients in two study groups

| Testicular volume | ≥35 mL (n=88) | <35 mL (n=93) | p-value |
|-------------------|---------------|---------------|---------|
| Age, yr           | 64.0±5.2      | 64.8±3.8      | 0.230   |
| Height, cm        | 168.5±5.7     | 167.0±5.7     | 0.079   |
| Weight, kg        | 69.2±9.8      | 66.0±9.1      | 0.024   |
| BMI, kg/m²        | 24.3±2.8      | 23.6±2.7      | 0.091   |
| Testosterone, ng/dL| 382.0±152.6   | 377.7±145.0   | 0.844   |
| Free testosterone, pg/mL | 8.06±3.25 | 7.83±2.72     | 0.618   |
| Testicular volume, mL | 42.6±5.3     | 27.2±4.7      | <0.001  |
| FVC, L            | 3.87±0.65     | 3.66±0.65     | 0.037   |
| FEV1, L           | 2.92±0.57     | 2.65±0.61     | 0.002   |
| FEV1/FVC, %       | 75.5±7.8      | 71.9±10.5     | 0.009   |
| PredFVC, %        | 98.2±15.2     | 93.8±13.1     | 0.040   |
| PredFEV1, %       | 105.4±19.5    | 95.9±21.2     | 0.002   |
| Smoking, n (%)    | 40/88 (45.5)  | 40/93 (43.0)  | 0.742   |
| Smoking, pack-years| 26.0±17.2    | 34.2±22.8     | 0.086   |
| FEV1/FVC <70%, n (%) | 14/88 (15.9) | 27/93 (29.0) | 0.034   |

BMI: body mass index; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 second; PredFVC: FVC % predicted; PredFEV1: FEV1 % predicted.

significant (95% CI, 1.046–4.464) (Table 5).
A number of chronic illnesses, including COPD, can cause hypogonadism. The mechanism of hypogonadism in COPD is multifactorial, and depends on aging, smoking, obesity, systemic inflammation, chronic disease itself, hypoxemia, hypercapnia, and the taking of glucocorticoids. COPD can affect the hypothalamic-pituitary-testicular axis at multiple levels. In one study, approximately 75% of men with COPD had a low serum testosterone level, a low or below-normal gonadotropin level. Reduced lung function and decline in lung function are associated with morbidity and mortality. However, the effects of sex hormones on lung function are not well understood. In a previous cross-sectional study conducted on 2,197 men, total and free testosterone levels were found to be positively and independently associated with FVC and FEV1, and men with severe pulmonary obstruction had lower free testosterone levels. However, another study found no relationship between free testosterone level and FEV1, residual volume, or total lung capacity. In present study, no relationship was observed between testosterone level and lung function. These discrepancies can be attributed to small sample sizes, differences in patient selection, and the inconsistent testosterone levels.

In an autopsy study, the total volume of Leydig cells in the testes of men with a history of chronic bronchitis and emphysema of at least 15 years’ duration, and with morphological evidence of the cardiopulmonary effects of hypoxia, was significantly less than the volume in matched controls. Other chronic conditions, such as, diabetes, stroke, and cancer, have also been associated with late-onset hypogonadism in men, and thus, it appears that a diminished testosterone level is common response to chronic disease. However, our findings of a linear association between testicular volume and pulmonary function may suggest a potential link between gonadal and pulmonary functions.

The literature is somewhat inconsistent regarding the relationship between smoking and testosterone levels. Most cross-sectional studies indicate that smoking increases total testosterone and that smoking cessation reduces testosterone levels in men. As SHBG levels are elevated in smoking men, it has been suggested that this reported increase in testosterone levels is a consequence of increased SHBG levels. However, Kirbas et al. studied the association between hypogonadism, smoking and obstructive sleep apnea and found no relationship between current smoking and testosterone levels. In the present study, univariate analysis using linear regression models showed that both testicular volume and testosterone levels were not correlated with smoking.

The human testis has been evaluated in terms of its endocrine function, daily sperm output in ejaculates, general appearance of seminiferous tubules, differential cell counts in the testis, and daily sperm production. Although many reports regarding Prader’s orchiometer-derived testicular volume are available, no uniform reference values are available, due to differences in the nature of the populations studied (geographic area, nutritional status, ethnicity, and environmental factors). The normal range of one testicular volume has been reported to be 14–30 mL, but human testicular volumes are markedly dependent on ethnicity. For example, testicular volumes have been reported to greater in Caucasian than in Oriental populations. As compared with the results of Auger and Eustache, our study population had smaller total testicular volumes (34.7±9.2 mL vs. 55.7±18.7 mL) (Table 1), and thus, it is not appropriate to compare our Korean data with Caucasian data directly. However, testicular volumes in this study were similar to those found in large-scale studies of healthy young Korean men, which means testicular volumes in our study population were within normal limits, as we excluded patients with conditions known to influence testicular volume.

Like lung function, clinically assessed testicular volume varies with age. In a large cohort of males aged 0–28 years, maximum testicular volume was attained at 17–18 and 21–22 years among non-gypsies and gypsies, respectively. Findings of testicular volume declines with aging are not universal, as some have reported a decrease and others no change. It has also been reported age, malnutrition and illness exert independent effects on testicular volume, and that age is associated with a reduction in testicular volume only in the eighth decade of life. However, recent studies suggest that

| Testicular volume | OR (95% CI) | p-value |
|-------------------|------------|---------|
| ≥35 mL            | <35 mL     |         |
| FEV1/FVC, %       |            |         |
| ≥70               | 74         | 66      | 2.162 (1.046–4.464) | 0.035 |
| <70               | 14         | 27      | 0.741             |       |
| Smoking           |            |         |
| Ever-smoker       | 40         | 40      | 1.104 (0.614–1.986) | 0.545 |
| Never-smoker      | 48         | 53      | 0.224–1.325       |       |
| Ever-smoker, pack-years | 19 | 30 | 0.545 (0.224–1.325) | 0.179 |

OR: odds ratio; CI: confidence interval; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity.
mild testicular volume decline often occurs earlier from the 50 or 60s11,42. Reduced testicular volume is associated with hormonal abnormalities, including low testosterone and increased luteininizing hormone (LH) and follicle-stimulating hormone (FSH) levels11,42. In aged men, testicular volume, testicular parenchymal weight, and daily sperm production are significantly reduced29. In addition, plasma LH, FSH, and estradiol concentrations are elevated whereas plasma testosterone, free testosterone, and the ability of the testis to secrete testosterone following stimulation are diminished. However, testosterone levels can fluctuate substantially day-to-day and sometimes within days. Therefore, testicular volume, which is relatively stable, represents androgen status better than a single measurement of testosterone level.

Several studies have reported a positive relationship exists between testicular volume and body weight11,17. In the present study, height, weight, and body mass index exhibited significant association with testicular volumes by univariate analysis (Table 2). However, body weight was not found to independently predict FEV1, % predicted by multivariate analysis (Table 2). In fact, only smoking and testicular volume were found to independently predict FEV1, % predicted (Table 3).

We enrolled the relatively small number of subjects from a specific setting. Furthermore, our results cannot be applied to other populations, given the limited demographics of the study population. Another limitation is that we used prebronchodilator spirometric values to evaluate lung function, and thus, we cannot rule out the possibility of transient airflow obstruction in some patients.

Summarizing, although the present study was not conducted using a large-scale, longitudinal design, it shows larger testicular volume was independently associated with favorable indices of lung function, and suggests that androgens may contribute to better lung function.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Laghi F, Langbein WE, Antonescu-Turcu A, Jubran A, Bamert C, Tobin MJ. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:598-605.
2. Kamischke A, Kemper DE, Castel MA, Luthke M, Rolf C, Behre HM, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998;11:41-5.
3. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724-31.
4. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002;87:589-98.
5. Daabas RG, Rehem RN, Hassan MM, Khalil GI. Hypogonadism in patients with chronic obstructive pulmonary disease: relationship with airflow limitation, muscle weakness and systemic inflammation. Alexandria J Med 2016;52:27-33.
6. Van Vliet M, Spruit MA, Verleden G, Kasran A, Van Herck E, Pitta F, et al. Hypogonadism, quadriiceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:1105-11.
7. Laghi F, Antonescu-Turcu A, Collins E, Segal J, Tobin DE, Jubran A, et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med 2005;171:728-33.
8. Debiregare B, Marquis K, Cote CH, Tremblay RR, Michaud A, LeBlanc P, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003;124:83-9.
9. Svarberg J, Schirmer H, Medbo A, Melbye H, Aasebo U. Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromso study. Eur J Epidemiol 2007;22:107-12.
10. Wheeler MJ, Barnes SC. Measurement of testosterone in the diagnosis of hypogonadism in the ageing male. Clin Endocrinol (Oxf) 2008;69:515-25.
11. Bahk JY, Jung JH, Jin LM, Min SK. Cut-off value of testes volume in young adults and correlation among testes volume, body mass index, hormonal level, and seminal profiles. Urol Res 2010;38:1318-23.
12. Sakamoto H, Ogawa Y, Yoshida H. Relationship between testicular volume and testicular function: comparison of the Prader orchidometric and ultrasonographic measurements in patients with infertility. Asian J Androl 2008;10:319-24.
13. Takihara H, Cosentino MJ, Sakatoku J, Cockett AT. Significance of testicular size measurement in andrology: II. Correlation of testicular size with testicular function. J Urol 1987;137:416-9.
14. Preston BT, Stevenson IR, Lincoln GA, Monfort SL, Pilkington JG, Wilson K. Testes size, testosterone production and reproductive behaviour in a natural mammalian mating system. J Anim Ecol 2012;81:296-305.
15. Rey RA, Campo SM, Bedecarras P, Nagle CA, Chemes HE. Is infancy a quiescent period of testicular development? Historical, morphometric, and functional study of the seminiferous tubules of the cebus monkey from birth to the end of puberty. J Clin Endocrinol Metab 1993;76:1325-31.
16. Ankarberg-Lindgren C, Norjavaara E. Changes of diurnal
rhythm and levels of total and free testosterone secretion from pre to late puberty in boys: testis size of 3 ml is a transition stage to puberty. Eur J Endocrinol 2004;151:747-57.

17. Ku JH, Kim ME, Jeon YS, Lee NK, Park YH. Factors influencing testicular volume in young men: results of a community-based survey. BJU Int 2002;90:446-50.

18. Fletcher C, Petro R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8.

19. Stearns EL, MacDonnell JA, Kaufman BJ, Padua R, Lucman TS, Winter JS, et al. Declining testicular function with age: hormonal and clinical correlates. Am J Med 1974;57:761-6.

20. Baker HW, Burger HG, de Kretser DM, Hudson B, O’Connor S, Wang C, et al. Changes in the pituitary-testicular system with age. Clin Endocrinol (Oxf) 1976;5:349-72.

21. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.

22. Vestbo J, Hurdl SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.

23. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am 2007;36:333-48.

24. Balasubramanian V, Naing S. Hypogonadism in chronic obstructive pulmonary disease: incidence and effects. Curr Opin Pulm Med 2012;18:112-7.

25. Gospney JR. Atrophy of Leydig cells in the testes of men with longstanding chronic bronchitis and emphysema. Thorax 1987;42:615-9.

26. Isidori AM, Lenzi A. Risk factors for androgen decline in older men: lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005;28(3 Suppl):14-22.

27. English KM, Pugh PJ, Parry H, Scutt NE, Channer KS, Jones TH. Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. Clin Sci (Lond) 2001;100:661-5.

28. Kirbas G, Abakay A, Topcu E, Kaplan A, Unlu M, Peker Y. Obstructive sleep apnoea, cigarette smoking and serum testosterone levels in a male sleep clinic cohort. J Int Med Res 2007;35:38-43.

29. Johnson L. Evaluation of the human testis and its age-related dysfunction. Prog Clin Biol Res 1989;302:35-60.